Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? (Q30242051)

12 June 2017

1 reference

title

Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? (English)

1 reference

12 June 2017

0 references

Adi J Klil-Drori

1

1 reference

12 June 2017

Laurent Azoulay

series ordinal

2

1 reference

12 June 2017

Michael N Pollak

series ordinal

3

1 reference

12 June 2017

language of work or name

English

0 references

publication date

9 August 2016

1 reference

Nature Reviews Clinical Oncology

12 June 2017

1 reference

12 June 2017

14

1 reference

12 June 2017

85-99

1 reference

12 June 2017

2

1 reference

Depletion of fat-resident Treg cells prevents age-associated insulin resistance

12 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Body-Mass Index and Mortality among 1.46 Million White Adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Association of Cardiometabolic Multimorbidity With Mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Global cancer statistics, 2012

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Global estimates of diabetes prevalence for 2013 and projections for 2035.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Global burden of cancer attributable to high body-mass index in 2012: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The contribution of fat and fat-free tissue to body mass index in contemporary children and the reference child

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Epidemiology: obesity and cancer--the evidence is fattening up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

A systematic review and meta-analysis of the relationship between body size and testicular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Obesity and incidence of lung cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Trajectory of body shape across the lifespan and cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Long-term mortality after gastric bypass surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Bariatric Surgery in the United Kingdom: A Cohort Study of Weight Loss and Clinical Outcomes in Routine Clinical Care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Adult weight change and risk of postmenopausal breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Intentional weight loss and incidence of obesity-related cancers: the Iowa Women's Health Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Cancer occurrence in Danish diabetic patients: duration and insulin effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Cancer detection rates following enrolment in a disease management programme for type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Diabetes and risk of prostate cancer: a study using the National Health Insurance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Obesity and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin and reduced risk of cancer in diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin and the risk of cancer: time-related biases in observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Insulin glargine and malignancy: an unwarranted alarm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

AACE/ACE comprehensive diabetes management algorithm 2015.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Investigating metformin for cancer prevention and treatment: the end of the beginning

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Proliferative effects of insulin analogues on mammary epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Sulfonylurea stimulation of insulin secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The insulin and insulin-like growth factor receptor family in neoplasia: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Pioglitazone--when is a prescription drug safe?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Examples of how the pharmaceutical industries distort the evidence of drug safety: the case of pioglitazone and the bladder cancer issue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Pioglitazone use and risk of bladder cancer: population based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Cancer cachexia: understanding the molecular basis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Obesity and the outcome of young breast cancer patients in the UK: the POSH study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Obesity-Associated Alterations in Inflammation, Epigenetics, and Mammary Tumor Growth Persist in Formerly Obese Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Obesity paradox: differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Diabetes mellitus, fasting glucose, and risk of cause-specific death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Does pre-existing diabetes affect prostate cancer prognosis? A systematic review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Type 2 diabetes and the risk of mortality among patients with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Pre-existing diabetes and breast cancer prognosis among elderly women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The use of metformin in patients with prostate cancer and the risk of death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin and prostate cancer mortality: a meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Do cancer cells care if their host is hungry?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Obesity and cancer: mechanistic insights from transdisciplinary studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Obesity and cancer: local and systemic mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Adiposity and cancer risk: new mechanistic insights from epidemiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

A Nested Case-Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

PTEN mutations as a cause of constitutive insulin sensitivity and obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Regulation of insulin-like growth factor-I in starvation and injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

IGF binding proteins in cancer: mechanistic and clinical insights

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

A prospective study of circulating adipokine levels and risk of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Molecular pathways: adiponectin and leptin signaling in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Obesity and Cancer: The Oil that Feeds the Flame

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Neutrophil ageing is regulated by the microbiome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Gut microbiota from twins discordant for obesity modulate metabolism in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Interactions between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to Obesity and Metabolic Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Diabetes in Cushing syndrome: basic and clinical aspects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The high incidence of steroid-induced hyperglycaemia in hospital

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Cancer-drug induced insulin resistance: innocent bystander or unusual suspect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Management of hyperglycemia in diabetic patients with hematologic malignancies during dexamethasone therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Insulin Increases De Novo Steroidogenesis in Prostate Cancer Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Drugging PI3K in cancer: refining targets and therapeutic strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Influence of glucocorticoids and growth hormone on insulin sensitivity in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Paradoxical effect of rapamycin on inflammatory stress-induced insulin resistance in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

mTOR inhibitors and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Adult life after childhood cancer in Scandinavia: diabetes mellitus following treatment for cancer in childhood.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Cancer and bone fractures in observational follow-up of the RECORD study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Pancreatic safety of newer incretin-based therapies: are the "-tides" finally turning?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.120

Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

31 March 2020

1 reference

12 December 2020

Prevalence of Obesity Among Adults and Youth: United States, 2011-2014.

1 reference

12 December 2020

Corticosteroids for the management of cancer-related pain in adults

1 reference

12 December 2020

NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis

1 reference

12 December 2020

The influence of the degree of caloric restriction on the formation of skin tumors and hepatomas in mice

1 reference

12 December 2020

10.1038/NRCLINONC.2016.120

Identifiers

DOI

1 reference

Dimensions Publication ID

12 June 2017

0 references

1 reference